medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2025, Number 2-3

<< Back Next >>

Arch Med Urg Mex 2025; 17 (2-3)

Tranexamic acid in the emergency department: an ally in the management of hemorrhages?

López-Salinas KG, Jiménez-Flores I, Arredondo-Armenta JM

Language: Spanish
References: 40
Page: 142-150
PDF size: 236.11 Kb.


ABSTRACT

The management of hemorrhages represents a significant challenge in emergency medicine, where there are situations in which hemorrhage control and hemodynamic stabilization are crucial for favorable outcomes. In this context, tranexamic acid (TXA), an antifibrinolytic agent, has emerged as a key intervention to reduce mortality associated with severe bleeding. Reviewed studies report that TXA has a good safety profile. Its intravenous administration has proven highly effective in managing obstetric and post-traumatic hemorrhage. In gastrointestinal bleeding, the evidence remains limited. Topical administration in cases of epistaxis is a safe option and more effective than conventional methods. In hematuria, the available information is still limited. Finally, nebulized administration has shown benefits in the management of hemoptysis, with minimal adverse effects. This review explores the different contexts in which tranexamic acid has been described, as well as the existing evidence surrounding its use.


REFERENCES

  1. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation.Blood Rev. 2015 Jan 1;29(1):17–24.

  2. Watts G. Utako Okamoto. Lancet. 2016 Jun 4;387(10035):2286.

  3. Dunn CJ, Goa KL, Benoni G. Tranexamic Acid A Review of itsUse in Surgery and Other Indications. Adis Drug Evaluation.1999;57(6):1005–31.

  4. Crash- T. The importance of early treatment with tranexamic acid inbleeding trauma patients: an exploratory analysis of the CRASH-2randomised controlled trial. The Lancet [Internet]. 2011;377:1096–101, 1101.e1-1101.e2. Available from: www.thelancet.com

  5. Ng W, Jerath A, Wasowicz M. Tranexamic acid: A clinical review.Anaesthesiol Intensive Ther. 2015;47(4):339–50.

  6. Lee PL, Yang KS, Tsai HW, Hou SK, Kang YN, Chang CC. Tranexamicacid for gastrointestinal bleeding: A systematic review withmeta-analysis of randomized clinical trials. American Journal ofEmergency Medicine. 2021 Jul 1;45:269–79.

  7. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS,Kurien M, et al. Diagnosis and management of nonvariceal uppergastrointestinal hemorrhage: European Society of GastrointestinalEndoscopy (ESGE) Guideline. Vol. 47, Endoscopy. Georg ThiemeVerlag; 2015. p. a1–46.

  8. Smith SR, Murray D, Pockney PG, Bendinelli C, Draganic BD, CarrollR. Tranexamic Acid for Lower GI Hemorrhage: A RandomizedPlacebo-Controlled Clinical Trial. Dis Colon Rectum. 2018 Jan1;61(1):99–106.

  9. Corry J, Kucki L. Management of Epistaxis - American Family Physician.Am Fam Physician [Internet]. 2005;2(2):305–11. Availablefrom: www.aafp.org/afp.

  10. Zahed R, Moharamzadeh P, Alizadeharasi S, Ghasemi A, SaeediM. A new and rapid method for epistaxis treatment using injectableform of tranexamic acid topically: A randomized controlled trial.American Journal of Emergency Medicine. 2013 Sep;31(9):1389–92.

  11. Birmingham AR, Mah ND, Ran R, Hansen M. Topical tranexamicacid for the treatment of acute epistaxis in the emergencydepartment. American Journal of Emergency Medicine. 2018 Jul1;36(7):1242–5.

  12. Tibbelin A, Aust Rudolf, Bende M, et.al. Effect of Local TranexamicAcid Gel in the Treatment of Epistaxis. Deparment of OtorhinolaryngologyCentral Hospital. 1995;207–9.

  13. Larici AR, Franchi P, Occhipinti M, Contegiacomo A, del Ciello A,Calandriello L, et al. Diagnosis and management of hemoptysis.Diagnostic and Interventional Radiology. 2014;20(4):299–309.

  14. Jeudy J, Khan AR, Mohammed TL, Amorosa JK, Brown K, DebraSue Dyer J, et al. ACR Appropriateness Criteria s Hemoptysis ExpertPanel on Thoracic Imaging. American College of Radiology[Internet]. 2010;25(3):67–9. Available from: www.thoracicimaging.com

  15. Calverley PMA, Albert P. Massive haemoptysis: the definitionshould be revised. European Respiratory Journal. 2008Oct;32(4):1131.

  16. Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapyto reduce haemoptysis from any cause. Cochrane Databaseof Systematic Reviews. 2012 Apr 18;2012(4).

  17. Kinoshita T, Ohbe H, Matsui H, Fushimi K, Ogura H, Yasunaga H.Effect of tranexamic acid on mortality in patients with haemoptysis:A nationwide study. Crit Care. 2019 Nov 6;23(1).

  18. Komura S, Rodriguez RM, Peabody CR. Hemoptysis? Try InhaledTranexamic Acid. Journal of Emergency Medicine. 2018 May1;54(5):e97–9.

  19. Hankerson MJ, Raffetto B, Mallon WK, Shoenberger JM. NebulizedTranexamic Acid as a Noninvasive Therapy for Cancer-RelatedHemoptysis. J Palliat Med. 2015 Dec 1;18(12):1060–2.

  20. Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L,Shitrit D. Inhaled Tranexamic Acid for Hemoptysis Treatment: ARandomized Controlled Trial. Chest. 2018 Dec 1;154(6):1379–84.

  21. Chan DYC, Tsang ACO, Li LF, Cheng KKF, Tsang FCP, Taw BBT,et al. Improving Survival with Tranexamic Acid in Cerebral Contusionsor Traumatic Subarachnoid Hemorrhage: Univariate andMultivariate Analysis of Independent Factors Associated withLower Mortality. World Neurosurg. 2019 May 1;125:e665–70.

  22. Xiong Y, Guo X, Huang X, Kang X, Zhou J, Chen C, et al. Efficacyand safety of tranexamic acid in intracranial haemorrhage: A meta-analysis. PLoS One. 2023 Mar 1;18(3 MARCH).

  23. Jiao X, Li M, Li L, Hu X, Guo X, Lu Y. Early Tranexamic Acid inIntracerebral Hemorrhage: A Meta-Analysis of Randomized ControlledTrials. Vol. 12, Frontiers in Neurology. Frontiers Media S.A.;2021.

  24. Sprigg N, Flaherty K, Appleton JP, Salman RAS, Bereczki D, BeridzeM, et al. Tranexamic acid for hyperacute primary IntraCerebralHaemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. The Lancet. 2018 May26;391(10135):2107–15.

  25. Mahmood A, Roberts I, Shakur H, Harris T, Belli A. Does tranexamicacid improve outcomes in traumatic brain injury? BMJ (Online).2016;354.

  26. Roberts I, Shakur-Still H, Aeron-Thomas A, Belli A, Brenner A,Chaudary MA, et al. Effects of tranexamic acid on death, disability,vascular occlusive events and other morbidities in patientswith acute traumatic brain injury (CRASH-3): A randomised, placebo-controlled trial. The Lancet. 2019 Nov 9;394(10210):1713–23.

  27. Jan H, Steen F, Ola Nilsson. Immediate administration of tranexamicacid and reduced incidence of early rebleeding after aneurysmalsubarachnoid hemorrhage: a prospective randomized study. JNeurosurg. 2002;97(1):771–8.

  28. Lethaby A. Antifibrinolytics for heavy menstrual bleeding (Review).Cochrane [Internet]. 2010;1–36. Available from: http://www.thecochranelibrary.com

  29. VanderMeulen H, Tang GH, Sholzberg M. Tranexamic acid for managementof heavy vaginal bleeding: barriers to access and mythssurrounding its use. Res Pract Thromb Haemost. 2024 Mar 1;8(3).

  30. Vogel JP, Oladapo OT, Dowswell T, Gülmezoglu AM. UpdatedWHO recommendation on intravenous tranexamic acid for thetreatment of post-partum haemorrhage. Lancet Glob Health. 2018Jan 1;6(1):e18–9.

  31. Ng W, Jerath A, Wasowicz M. Tranexamic acid: A clinical review.Anaesthesiol Intensive Ther. 2015;47(4):339–50.

  32. Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, AkintanA, et al. Effect of early tranexamic acid administration onmortality, hysterectomy, and other morbidities in women withpost-partum haemorrhage (WOMAN): an international, randomised,double-blind, placebo-controlled trial. The Lancet. 2017 May27;389(10084):2105–16.

  33. Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX,Roberts I, et al. Effect of treatment delay on the effectivenessand safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleedingpatients. The Lancet. 2018 Jan 13;391(10116):125–32.

  34. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C,Keita-Meyer H, et al. High-dose tranexamic acid reduces bloodloss in postpartum haemorrhage. Crit Care. 2011 Apr 15;15(2).

  35. Gungorduk K, Yildirim G, Asicioǧlu O, Gungorduk OC, SudolmusS, Ark C. Efficacy of intravenous tranexamic acid in reducingblood loss after elective cesarean section: A prospective, randomized,double-blind, placebo-controlled study. Am J Perinatol.2011;28(3):233–9.

  36. Gungorduk K, Asicioǧlu O, Yildirim G, Ark C, Tekirdaǧ A, BesimogluB. Can intravenous injection of tranexamic acid be used in routinepractice with active management of the third stage of labor invaginal delivery? A randomized controlled study. Am J Perinatol.2013;30(5):407–13.

  37. Willis GC, Tewelde SZ. The Approach to the Patient with Hematuria.Emerg Med Clin North Am. 2019 Nov 1;37(4):755–69.

  38. Ma TKW, Chow KM, Kwan BCH, Leung CB, Szeto CC, Li PKT.Manifestation of tranexamic acid toxicity in chronic kidney diseaseand kidney transplant patients: A report of four cases and reviewof literature. Nephrology. 2017 Apr 1;22(4):316–21.

  39. Andersson L, Eriksson O, Hedlund PO, Kjellman H, Lindqvist B.Urological Research Special Considerations with Regard to theDosage of Tranexamic Acid in Patients with Chronic Renal Diseases.Urol Res. 1978;6:83–8.

  40. Yao Q, Wu M, Zhou J, Zhou M, Chen D, Fu L, et al. Treatment ofpersistent gross hematuria with tranexamic acid in autosomal dominantpolycystic kidney disease. Kidney Blood Press Res. 2017May 1;42(1):156–64.




2020     |     www.medigraphic.com